CPT® Code 38210

1. Indications

The procedure described by CPT® Code 38210 is indicated for the following conditions:

• Allogeneic Transplant Procedures T-cell depletion is performed to reduce the risk of graft-versus-host disease (GVHD) in patients receiving hematopoietic progenitor cells from a donor.

2. Procedure

The procedure for CPT® Code 38210 involves several critical steps to ensure the effective harvesting and preparation of hematopoietic progenitor cells.

• Step 1: Blood Collection The process begins with the collection of blood from the donor, which contains the hematopoietic progenitor cells. This is typically done through apheresis, a procedure that separates the blood components and allows for the collection of specific cells while returning the remaining components back to the donor.
• Step 2: T-cell Depletion Once the blood is collected, it is processed through an automated device designed to deplete T-cells. This device utilizes specific techniques to passively remove T-cells and other unwanted cells from the harvested progenitor cells, ensuring that the final product is enriched with the desired hematopoietic progenitor cells.
• Step 3: Quality Assessment After the T-cell depletion process, a quality assessment is performed on the transplant product. This assessment is crucial to confirm that the T-cells and other undesired cells have been sufficiently depleted. The quality check ensures that the harvested cells are suitable for transplantation, which is vital for the success of the procedure.
• Step 4: Cryopreservation and Storage Following the quality assessment, any necessary cryopreservation and storage of the hematopoietic progenitor cells are conducted. This step is essential to maintain the viability of the cells until they are needed for the transplant procedure. The cryopreservation process involves freezing the cells at very low temperatures to preserve their function and integrity.

3. Post-Procedure

Post-procedure care for patients undergoing T-cell depletion during hematopoietic progenitor cell harvesting typically involves monitoring for any potential complications related to the apheresis process. Patients may experience some side effects from the blood collection, such as fatigue or mild discomfort at the venipuncture site. Additionally, the quality of the harvested cells is closely monitored to ensure they meet the necessary standards for transplantation. Once the cells are cryopreserved, they can be stored for future use, and the patient will be prepared for the subsequent transplant procedure, which may involve additional pre-transplant conditioning regimens.